Prospective study of prevention of recurrence of prostate cancer with bone metastasis and prevention of bone mineral density decrease by combination therapy with hormonal therapy and zoledronic acid

Trial Profile

Prospective study of prevention of recurrence of prostate cancer with bone metastasis and prevention of bone mineral density decrease by combination therapy with hormonal therapy and zoledronic acid

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top